Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kader Konde

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Vaccine|May 25, 2007
The Meningitis Vaccine ProjectF Marc LaForce, Kader Konde, Simonetta Viviani, et al.
Clinical Trials (London, England)|January 16, 2016
Clinical research during the Ebola virus disease outbreak in Guinea: Lessons learned and ways forwardAbdoul Habib Beavogui, Alexandre Delamou, Mohamed Lamine Yansane, et al.
The Journal of Infectious Diseases|May 2, 2003
Measles incidence before and after mass vaccination campaigns in Burkina FasoChantal Kambiré, M Kader Konde, André Yaméogo, et al.
Mbio|April 21, 2022
Plasma Proteomic Analysis Distinguishes Severity Outcomes of Human Ebola Virus DiseaseArthur Viodé, Kinga K Smolen, Benoit Fatou, et al.
Virus Evolution|July 20, 2022
The characterization of multiple novel paramyxoviruses highlights the diverse nature of the subfamily <i>Orthoparamyxovirinae</i>Bert Vanmechelen, Sien Meurs, Marie Horemans, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2012
An outbreak of wild poliovirus in the Republic of Congo, 2010-2011Minal K Patel, Mandy Kader Konde, Boris Hermann Didi-Ngossaki, et al.
Scientific Reports|September 2, 2020
Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodiesKimberley Steeds, Yper Hall, Gillian S Slack, et al.
Frontiers in Immunology|May 2, 2022
Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and PathogenesisJack Mellors, Tom Tipton, Sarah Katharina Fehling, et al.
Plos Medicine|December 2, 2015
Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort StudyOumar Faye, Alessio Andronico, Ousmane Faye, et al.
Plos One|February 23, 2017
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trialMandy Kader Konde, Darren P Baker, Fode Amara Traore, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Vaccine|May 25, 2007
The Meningitis Vaccine ProjectF Marc LaForce, Kader Konde, Simonetta Viviani, et al.
Clinical Trials (London, England)|January 16, 2016
Clinical research during the Ebola virus disease outbreak in Guinea: Lessons learned and ways forwardAbdoul Habib Beavogui, Alexandre Delamou, Mohamed Lamine Yansane, et al.
The Journal of Infectious Diseases|May 2, 2003
Measles incidence before and after mass vaccination campaigns in Burkina FasoChantal Kambiré, M Kader Konde, André Yaméogo, et al.
Mbio|April 21, 2022
Plasma Proteomic Analysis Distinguishes Severity Outcomes of Human Ebola Virus DiseaseArthur Viodé, Kinga K Smolen, Benoit Fatou, et al.
Virus Evolution|July 20, 2022
The characterization of multiple novel paramyxoviruses highlights the diverse nature of the subfamily <i>Orthoparamyxovirinae</i>Bert Vanmechelen, Sien Meurs, Marie Horemans, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2012
An outbreak of wild poliovirus in the Republic of Congo, 2010-2011Minal K Patel, Mandy Kader Konde, Boris Hermann Didi-Ngossaki, et al.
Scientific Reports|September 2, 2020
Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodiesKimberley Steeds, Yper Hall, Gillian S Slack, et al.
Frontiers in Immunology|May 2, 2022
Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and PathogenesisJack Mellors, Tom Tipton, Sarah Katharina Fehling, et al.
Plos Medicine|December 2, 2015
Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort StudyOumar Faye, Alessio Andronico, Ousmane Faye, et al.
Plos One|February 23, 2017
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trialMandy Kader Konde, Darren P Baker, Fode Amara Traore, et al.
Pageof 2